wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q36862301-4588A904-EC68-4D38-A89D-3E1C339B256A
Q36862301-4588A904-EC68-4D38-A89D-3E1C339B256A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36862301-4588A904-EC68-4D38-A89D-3E1C339B256A
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.
P2860
Q36862301-4588A904-EC68-4D38-A89D-3E1C339B256A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36862301-4588A904-EC68-4D38-A89D-3E1C339B256A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
602a149bf8b47dc5bd4f13074de2222c3f544489
P2860
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.